AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-100 | >>
Results: 1-25/123
EXPRESSION OF CD86 ON HUMAN MARROW CD34(+) CELLS IDENTIFIES IMMUNOCOMPETENT COMMITTED PRECURSORS OF MACROPHAGES AND DENDRITIC CELLS
Authors: RYNCARZ RE ANASETTI C
Citation: Re. Ryncarz et C. Anasetti, EXPRESSION OF CD86 ON HUMAN MARROW CD34(+) CELLS IDENTIFIES IMMUNOCOMPETENT COMMITTED PRECURSORS OF MACROPHAGES AND DENDRITIC CELLS, Blood, 91(10), 1998, pp. 3892-3900
ROLE OF CD28 IN ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD)
Authors: YU XZ MARTIN PJ ANASETTI C
Citation: Xz. Yu et al., ROLE OF CD28 IN ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD), The FASEB journal, 12(5), 1998, pp. 6337-6337
EFFECT OF HLA MATCHING ON OUTCOME OF RELATED AND UNRELATED DONOR TRANSPLANTATION THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA
Authors: PETERSDORF E ANASETTI C SERVIDA P MARTIN P HANSEN J
Citation: E. Petersdorf et al., EFFECT OF HLA MATCHING ON OUTCOME OF RELATED AND UNRELATED DONOR TRANSPLANTATION THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA, Hematology/oncology clinics of North America, 12(1), 1998, pp. 107
INITIAL THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA - PLAYING THE ODDS
Authors: LEE SJ ANASETTI C HOROWITZ MM ANTIN JH
Citation: Sj. Lee et al., INITIAL THERAPY FOR CHRONIC MYELOGENOUS LEUKEMIA - PLAYING THE ODDS, Journal of clinical oncology, 16(9), 1998, pp. 2897-2903
ALLOIMMUNE FUNCTIONS OF HEALTHY DONOR G-CSF MOBILIZED BLOOD-CELLS
Authors: RONDELLI D RASPADORI D ANASETTI C BANDINI G LEMOLI RM ARPINATI M RE F MORELLI A BACCINI C ZACCARIA A TURA S
Citation: D. Rondelli et al., ALLOIMMUNE FUNCTIONS OF HEALTHY DONOR G-CSF MOBILIZED BLOOD-CELLS, Experimental hematology, 26(8), 1998, pp. 31-31
ALLOANTIGEN PRESENTING CAPACITY, T-CELL ALLOREACTIVITY AND NK FUNCTION OF G-CSF-MOBILIZED PERIPHERAL-BLOOD CELLS
Authors: RONDELLI D RASPADORI D ANASETTI C BANDINI G RE F ARPINATI M STANZANI M MORELLI A BACCINI C ZACCARIA A LEMOLI RM TURA S
Citation: D. Rondelli et al., ALLOANTIGEN PRESENTING CAPACITY, T-CELL ALLOREACTIVITY AND NK FUNCTION OF G-CSF-MOBILIZED PERIPHERAL-BLOOD CELLS, Bone marrow transplantation, 22(7), 1998, pp. 631-637
REPRODUCIBILITY IN RETROSPECTIVE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC MARROW TRANSPLANTATION
Authors: MARTIN P NASH R SANDERS J LEISENRING W ANASETTI C DEEG HJ STORB R APPELBAUM F
Citation: P. Martin et al., REPRODUCIBILITY IN RETROSPECTIVE GRADING OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC MARROW TRANSPLANTATION, Bone marrow transplantation, 21(3), 1998, pp. 273-279
T-CELL ALLOREACTIVITY INDUCED BY NORMAL G-CSF-MOBILIZED CD34(-CELLS()BLOOD)
Authors: RONDELLI D ANASETTI C FORTUNA A RATTA M ARPINATI M BANDINI G LEMOLI RM TURA S
Citation: D. Rondelli et al., T-CELL ALLOREACTIVITY INDUCED BY NORMAL G-CSF-MOBILIZED CD34(-CELLS()BLOOD), Bone marrow transplantation, 21(12), 1998, pp. 1183-1191
BONE-MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA
Authors: HANSEN JA GOOLEY TA MARTIN PJ APPELBAUM F CHAUNCEY TR CLIFT RA PETERSDORF EW RADICH J SANDERS JE STORB RF SULLIVAN KM ANASETTI C
Citation: Ja. Hansen et al., BONE-MARROW TRANSPLANTS FROM UNRELATED DONORS FOR PATIENTS WITH CHRONIC MYELOID-LEUKEMIA, The New England journal of medicine, 338(14), 1998, pp. 962-968
PHARMACOKINETICS OF CYCLOPHOSPHAMIDE AND ITS METABOLITES IN BONE-MARROW TRANSPLANTATION PATIENTS
Authors: REN S KALHORN TF MCDONALD GB ANASETTI C APPELBAUM FR SLATTERY JT
Citation: S. Ren et al., PHARMACOKINETICS OF CYCLOPHOSPHAMIDE AND ITS METABOLITES IN BONE-MARROW TRANSPLANTATION PATIENTS, Clinical pharmacology and therapeutics, 64(3), 1998, pp. 289-301
METHODS FOR ASSESSMENT OF GRAFT-VERSUS-HOST DISEASE
Authors: MARTIN PJ SCHOCH G GOOLEY T ANASETTI C DEEG HJ NASH R SANDERS J STORB R APPELBAUM F
Citation: Pj. Martin et al., METHODS FOR ASSESSMENT OF GRAFT-VERSUS-HOST DISEASE, Blood, 92(9), 1998, pp. 3479-3480
DECREASED REJECTION AND IMPROVED SURVIVAL OF FIRST AND 2ND MARROW TRANSPLANTS FOR SEVERE APLASTIC-ANEMIA (A 26-YEAR RETROSPECTIVE ANALYSIS)
Authors: STUCKI A LEISENRING W SANDMAIER BM SANDERS J ANASETTI C STORB R
Citation: A. Stucki et al., DECREASED REJECTION AND IMPROVED SURVIVAL OF FIRST AND 2ND MARROW TRANSPLANTS FOR SEVERE APLASTIC-ANEMIA (A 26-YEAR RETROSPECTIVE ANALYSIS), Blood, 92(8), 1998, pp. 2742-2749
ROLE OF CD28 IN ACUTE GRAFT-VERSUS-HOST DISEASE
Authors: YU XZ MARTIN PJ ANASETTI C
Citation: Xz. Yu et al., ROLE OF CD28 IN ACUTE GRAFT-VERSUS-HOST DISEASE, Blood, 92(8), 1998, pp. 2963-2970
ASSOCIATION BETWEEN PRETRANSPLANT INTERFERON-ALPHA AND OUTCOME AFTER UNRELATED DONOR MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
Authors: MORTON AJ GOOLEY T HANSEN JA APPELBAUM FR BRUEMMER B BJERKE JW CLIFT R MARTIN PJ PETERSDORF EW SANDERS JE STORB R SULLIVAN KM WOOLFREY A ANASETTI C
Citation: Aj. Morton et al., ASSOCIATION BETWEEN PRETRANSPLANT INTERFERON-ALPHA AND OUTCOME AFTER UNRELATED DONOR MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE, Blood, 92(2), 1998, pp. 394-401
THE COSTS AND COST-EFFECTIVENESS OF UNRELATED DONOR BONE-MARROW TRANSPLANTATION FOR CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
Authors: LEE SJ ANASETTI C KUNTZ KM PATTEN J ANTIN JH WEEKS JC
Citation: Sj. Lee et al., THE COSTS AND COST-EFFECTIVENESS OF UNRELATED DONOR BONE-MARROW TRANSPLANTATION FOR CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA, Blood, 92(11), 1998, pp. 4047-4052
OPTIMIZING OUTCOME AFTER UNRELATED MARROW TRANSPLANTATION BY COMPREHENSIVE MATCHING OF HLA CLASS-I AND CLASS-II ALLELES IN THE DONOR AND RECIPIENT
Authors: PETERSDORF EW GOOLEY TA ANASETTI C MARTIN PJ SMITH AG MICKELSON EM WOOLFREY AE HANSEN JA
Citation: Ew. Petersdorf et al., OPTIMIZING OUTCOME AFTER UNRELATED MARROW TRANSPLANTATION BY COMPREHENSIVE MATCHING OF HLA CLASS-I AND CLASS-II ALLELES IN THE DONOR AND RECIPIENT, Blood, 92(10), 1998, pp. 3515-3520
BONE-MARROW TRANSPLANTATION FOR CHILDREN LESS-THAN 2 YEARS OF AGE WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME
Authors: WOOLFREY AE GOOLEY TA SIEVERS EL MILNER LA ANDREWS RG WALTERS M HOFFMEISTER P HANSEN JA ANASETTI C BRYANT E APPELBAUM FR SANDERS JE
Citation: Ae. Woolfrey et al., BONE-MARROW TRANSPLANTATION FOR CHILDREN LESS-THAN 2 YEARS OF AGE WITH ACUTE MYELOGENOUS LEUKEMIA OR MYELODYSPLASTIC SYNDROME, Blood, 92(10), 1998, pp. 3546-3556
ALLOGRAFTING FOR CHRONIC MYELOID-LEUKEMIA
Authors: CLIFT RA ANASETTI C
Citation: Ra. Clift et C. Anasetti, ALLOGRAFTING FOR CHRONIC MYELOID-LEUKEMIA, Bailliere's clinical haematology, 10(2), 1997, pp. 319-336
CHARACTERIZATION OF CYTOTOXIC T-CELLS THAT RECOGNIZE DONOR HLA-C ALLOANTIGENS AS THE CAUSE OF GRAFT-REJECTION AFTER MARROW TRANSPLANTATION
Authors: PEI J AKATSUKA Y ANASETTI C PETERSDORF EW DAVIS J GARCIA M FARRAND A SMITH A LIN MT HANSEN JA
Citation: J. Pei et al., CHARACTERIZATION OF CYTOTOXIC T-CELLS THAT RECOGNIZE DONOR HLA-C ALLOANTIGENS AS THE CAUSE OF GRAFT-REJECTION AFTER MARROW TRANSPLANTATION, Human immunology, 55, 1997, pp. 30-30
HEMATOPOIETIC STEM-CELL TRANSPLANTS FROM UNRELATED DONORS
Authors: HANSEN JA PETERSDORF E MARTIN PJ ANASETTI C
Citation: Ja. Hansen et al., HEMATOPOIETIC STEM-CELL TRANSPLANTS FROM UNRELATED DONORS, Immunological reviews, 157, 1997, pp. 141-151
HUMAN IGG2 VARIANTS OF CHIMERIC ANTI-CD3 ARE NONMITOGENIC TO T-CELLS
Authors: COLE MS ANASETTI C TSO JY
Citation: Ms. Cole et al., HUMAN IGG2 VARIANTS OF CHIMERIC ANTI-CD3 ARE NONMITOGENIC TO T-CELLS, The Journal of immunology, 159(7), 1997, pp. 3613-3621
MARROW TRANSPLANTS FROM UNRELATED DONORS FOR TREATMENT OF PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: SIERRA J RADICH J HANSEN JA MARTIN PJ PETERSDORF EW BJERKE J BRYANT E NASH RA SANDERS JE STORB R SULLIVAN KM APPELBAUM FR ANASETTI C
Citation: J. Sierra et al., MARROW TRANSPLANTS FROM UNRELATED DONORS FOR TREATMENT OF PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA, Blood, 90(4), 1997, pp. 1410-1414
CONVERSION TO FK506 FOR CYCLOSPORINE (CSP)-RESISTANT ACUTE GVHD OR CSP-ASSOCIATED TOXICITY
Authors: FURLONG T STORB R ANASETTI C APPELBAUM F DEEG HJ DONEY K MARTIN P SULLIVAN KM WITHERSPOON R NASH RA
Citation: T. Furlong et al., CONVERSION TO FK506 FOR CYCLOSPORINE (CSP)-RESISTANT ACUTE GVHD OR CSP-ASSOCIATED TOXICITY, Blood, 90(10), 1997, pp. 458-458
MYCOPHENOLATE MOFETIL (MMF) AS SALVAGE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT) - SAFETY ANALYSIS
Authors: NASH RA FURLONG T STORB R ANASETTI C APPELBAUM FR DEEG HJ DONEY K MARTIN P WITHERSPOON R SULLIVAN KM
Citation: Ra. Nash et al., MYCOPHENOLATE MOFETIL (MMF) AS SALVAGE TREATMENT FOR GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER ALLOGENEIC HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT) - SAFETY ANALYSIS, Blood, 90(10), 1997, pp. 459-459
THE COST-EFFECTIVENESS OF UNRELATED DONOR BONE-MARROW TRANSPLANTATION(URD BMT) FOR CHRONIC MYELOGENOUS LEUKEMIA (CML)
Authors: LEE SJ ANASETTI C KUNTZ KM PATTEN J ANTIN JH WEEKS JC
Citation: Sj. Lee et al., THE COST-EFFECTIVENESS OF UNRELATED DONOR BONE-MARROW TRANSPLANTATION(URD BMT) FOR CHRONIC MYELOGENOUS LEUKEMIA (CML), Blood, 90(10), 1997, pp. 472-472
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>